- Home
- A-Z Publications
- Current Vascular Pharmacology
- Previous Issues
- Volume 7, Issue 3, 2009
Current Vascular Pharmacology - Volume 7, Issue 3, 2009
Volume 7, Issue 3, 2009
-
-
Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention]
The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease (ESRD). The reasons for this and previous negative findings are discussed. In contrast, there is evidence th Read More
-
-
-
Expression and Function of Anti-Inflammatory Interleukins: The Other Side of the Vascular Response to Injury
Authors: Anthony A. Cuneo and Michael V. AutieriCommon to multiple vascular diseases, including atherosclerosis, interventional restenosis, and transplant vasculopathy, is a localized inflammatory reaction. Activated vascular smooth muscle cells (VSMC) respond to local inflammation and migrate from the media into the lumen of the vessel where they proliferate and synthesize cytokines which they respond to in an autocrine fashion, sustaining the progression of the lesion. Read More
-
-
-
Future Challenges for Microsomal Transport Protein Inhibitors
Authors: Anthony S. Wierzbicki, Tim Hardman and William T. PrinceAtherosclerosis is a leading cause of morbidity and mortality worldwide. Statins are established as first choice drugs for the management of hyperlipidaemia and cardiovascular risk. However, a residual cardiovascular risk, partially attributable to lipids, remains even after statin treatment. This risk appears to be associated with both high-density lipoprotein cholesterol and triglyceride lipid fractions. Several novel therapeutic Read More
-
-
-
The Complement Cascade: New Avenues in Stroke Therapy
Recent evidence has shown that after the initial occlusion, a large portion of stroke patients achieve some degree of reperfusion either through collateral circulation or clot dissolution. However, it appears that this reperfusion may lead to increased inflammation-induced damage. Even though the exact mechanism of this secondary injury is unclear, several experimental studies have indicated an intimate connection bet Read More
-
-
-
Ginseng Compounds: An Update on their Molecular Mechanisms and Medical Applications
Authors: Jian-Ming Lu, Qizhi Yao and Changyi ChenGinseng is one of the most widely used herbal medicines and is reported to have a wide range of therapeutic and pharmacological applications. Ginsenosides, the major pharmacologically active ingredients of ginseng, appear to be responsible for most of the activities of ginseng including vasorelaxation, antioxidation, anti-inflammation and anticancer. Approximately 40 ginsenoside compounds have been identified. Resear Read More
-
-
-
Pharmacological Agents in the Treatment of Venous Disease: An Update of the Available Evidence
Authors: Manjit S. Gohel and Alun H. DaviesVaricose veins and the complications of venous disease are thought to affect over a quarter of the adult population and the management of these conditions are a major cause of health service expense. Advances in the understanding of venous pathophysiology have highlighted numerous potential targets for pharmacotherapy. This review considers the evidence for pharmacological agents used for the treatment of chroni Read More
-
-
-
New Anticoagulants: Focus on Venous Thromboembolism
Authors: Antonio Gomez-Outes, Ramon Lecumberri, Carmen Pozo and Eduardo RochaAnticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) and/or arterial thromboembolism. The therapeutic arsenal of anticoagulants available to clinicians is mainly composed by unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), fondaparinux and oral vitamin K antagonists (VKA) (i.e. warfarin and acenocumar Read More
-
-
-
Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management
Authors: Arrigo F.G. Cicero, Sibel Ertek and Claudio BorghiOmega-3 (ω-3) polyunsaturated fatty acids (PUFAs) from fish and fish oils appear to protect against coronary heart disease: their dietary intake is in fact inversely associated with cardiovascular disease morbidity/mortality in population studies. Recent evidence suggests that at least a part of this protective effect is mediated by a relatively small but significant decrease in blood pressure (BP) level. In fact, ω-3 PUFAs exhibit wide-ra Read More
-
-
-
Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Ultrasound contrast agents, consisting of gas-filled microbubbles, have long been used to enhance ultrasonographic imaging of various organs and in several settings. In echocardiography, after their first use for Doppler signal enhancement, their applications have expanded and several studies, combining a range of stress modalities with myocardial contrast echocardiography have shown the clinical utility of these agents. In exp Read More
-
-
-
Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Authors: Daniela Grimm, Johann Bauer and Johann SchoenbergerNeoangiogenesis, the development of new blood vessels from a pre-existing vasculature involves the migration behavior, proliferation and differentiation of endothelial cells. This process is an important aspect to both the growth and metastasis of solid tumors. In growing tumors, the development of a sufficient vascular supply is a highly complex event, which is controlled by many factors. An interaction between tumo Read More
-
-
-
Role of Pharmacotherapy in Cardiac Ion Channelopathies
Authors: Nabil El-Sherif, Ronald Pedalino and Herman Himel IVIn the last decade there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VA) and Sudden Cardiac Death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10-15% of SCD occurs in the presence of structurally normal heart and the majority of those patients are young. In this group of patients, changes in ge Read More
-
-
-
Clinical Aspects of Melatonin in the Acute Coronary Syndrome
Authors: Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez and Russel J. ReiterThis review considers the actions of an endogenously produced molecule, melatonin, on heart diseases. Recent research has shown that inflammation plays a key role in coronary heart disease (CHD) and other manifestations of atherosclerosis. Immune cells dominate early atherosclerotic lesions, their effector molecules accelerate progression of the lesions and activation of inflammation can elicit acute cor Read More
-
-
-
Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification
Authors: Diego Brancaccio, Antonio Bellasi, Mario Cozzolino, Andrea Galassi and Maurizio GallieniChronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism that occurs in Chronic Kidney Disease (CKD). In addition to abnormalities in serum calcium (Ca) and phosphate (P) profile, CKD-MBD is characterized by abnormalities of bone turnover, mineralization, volume and growth as well as vascular calcification (VC). Indeed, the co-localization of bone markers such as O Read More
-
-
-
Mesenchymal Stem Cells: A Good Candidate for Restenosis Therapy?
Authors: Amalia Forte, Umberto Galderisi, Marilena Cipollaro and Antonino CascinoRestenosis is a pathophysiological phenomenon that can occur in patients submitted to revascularization procedures (bypass, endarterectomy, angioplasty), possibly resulting in new narrowing of injured vessels. Vascular restenosis remains a pressing clinical problem, despite the therapeutic strategies and devices developed so far. Stem cells hold a great potential for the regeneration of damaged tissues in cardiovascular dise Read More
-
-
-
Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Authors: Roberto A. Mangiafico and Carmelo E. FioreLower extremity peripheral arterial disease (PAD) is a manifestation of atherosclerosis, with a prevalence ranging from 4% to 12% in the adult population and increasing up to 20% in older individuals. Intermittent claudication (IC) may markedly impair walking ability, overall functional status and quality of life. PAD is a marker of systemic atherosclerosis and is associated with increased cardiovascular morbidity and mortality. Read More
-
-
-
Vitamin D and Cardiovascular Disease
Authors: Ioanna Gouni-Berthold, Wilhelm Krone and Heiner K. BertholdCardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Recently vitamin D deficiency has been identified as a potential risk factor for many diseases not traditionally associated with vitamin D, such as cancer and CVD. This review discusses the evidence suggesting an association between low 25-hydroxyvitamin D levels and CVD and the possible mechanisms mediating it. Vitamin D deficie Read More
-
Volumes & issues
-
Volume 23 (2025)
-
Volume 22 (2024)
-
Volume 21 (2023)
-
Volume 20 (2022)
-
Volume 19 (2021)
-
Volume 18 (2020)
-
Volume 17 (2019)
-
Volume 16 (2018)
-
Volume 15 (2017)
-
Volume 14 (2016)
-
Volume 13 (2015)
-
Volume 12 (2014)
-
Volume 11 (2013)
-
Volume 10 (2012)
-
Volume 9 (2011)
-
Volume 8 (2010)
-
Volume 7 (2009)
-
Volume 6 (2008)
-
Volume 5 (2007)
-
Volume 4 (2006)
-
Volume 3 (2005)
-
Volume 2 (2004)
-
Volume 1 (2003)
Most Read This Month
Article
content/journals/cvp
Journal
10
5
false
en
